Future Market Insights (FMI) forecasts the ethoxyquin market to exhibit 3.5% CAGR between 2022 and 2030. Despite an overall positive outlook, FMI fears stunted growth amid ban imposed on ethoxyquin use in the EU. Nonetheless, growth is expected to remain steady in North America, backed by FDA approval on ethoxyquin (EQ) use in specified limit. FMI offers an executive-level …